[HTML][HTML] Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma
MW Rohaan, TH Borch, JH Van Den Berg… - New England journal …, 2022 - Mass Medical Soc
Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
S Klobuch, TTP Seijkens, TN Schumacher… - Nature Reviews …, 2024 - nature.com
Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF
and MEK inhibitors have revolutionized the treatment of melanoma over the past decade …
and MEK inhibitors have revolutionized the treatment of melanoma over the past decade …
[HTML][HTML] Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and …
Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has been
tested in advanced melanoma patients at various centers. We conducted a systematic …
tested in advanced melanoma patients at various centers. We conducted a systematic …
Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future
A Betof Warner, PG Corrie, O Hamid - Clinical Cancer Research, 2023 - AACR
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is gaining momentum and
demonstrating durable responses in patients with advanced melanoma. Although …
demonstrating durable responses in patients with advanced melanoma. Although …
[HTML][HTML] Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
TH Borch, R Andersen, E Ellebaek, Ö Met… - … for ImmunoTherapy of …, 2020 - ncbi.nlm.nih.gov
Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating
lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s …
lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s …
Tumor-infiltrating lymphocytes in melanoma
S Lee, K Margolin - Current oncology reports, 2012 - Springer
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is arguably the most effective
treatment for patients with metastatic melanoma. With higher response rates than ipilimumab …
treatment for patients with metastatic melanoma. With higher response rates than ipilimumab …
Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma
JE Mullinax, ML Hall, S Prabhakaran, J Weber… - Frontiers in …, 2018 - frontiersin.org
Purpose Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic
melanoma can be highly effective, but attrition due to progression before TIL administration …
melanoma can be highly effective, but attrition due to progression before TIL administration …
Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome
Purpose: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has
consistently demonstrated clinical efficacy in metastatic melanoma. Recent widespread use …
consistently demonstrated clinical efficacy in metastatic melanoma. Recent widespread use …
Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.
A Sarnaik, HM Kluger, JA Chesney, J Sethuraman… - 2017 - ascopubs.org
3045 Background: Adoptive cell therapy with TIL involves collection of autologous
lymphocytes from the tumor via surgical resection, ex vivo expansion of TIL …
lymphocytes from the tumor via surgical resection, ex vivo expansion of TIL …
[HTML][HTML] Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression …
J Chesney, KD Lewis, H Kluger, O Hamid… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Patients with advanced melanoma have limited treatment options after
progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor …
progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor …